Citi placed an “upside 90-day catalyst watch” on shares of Ideaya Biosciences (IDYA) while keeping a Buy rating on the name with a $65 price target Citi sees a favorable share setup into the Phase 2/3 data OptimUM-02 trial expected in late March in HLA*A2-negative metastatic uveal melanoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences enrolls first patient in IDE034 trial
- IDEAYA Biosciences: Methodologically De-Risked OpTimUM-02 Readout and Strong Cash Runway Support Buy Rating
- Ideaya Biosciences appoints Theodora Ross as chief development officer
- IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating
- Ideaya Biosciences price target raised to $65 from $64 at Citi